Last reviewed · How we verify
QLT091001
At a glance
| Generic name | QLT091001 |
|---|---|
| Sponsor | QLT Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase 2/3 Study of ALK-001 in Geographic Atrophy (PHASE2, PHASE3)
- The Effect of Multiple Micronutrient Supplements in Reducing Anemia in Women of Reproductive Age (NA)
- Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease (PHASE2)
- Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE) (PHASE2)
- Phase 1 Safety Study of ALK-001 in Healthy Volunteers (PHASE1)
- Validation and Simplification of the Retinol Isotope Dilution Technique in Burkinabe Schoolchildren
- Healthy Mums, Healthy Babies: Multiple Micronutrient Supplementation in Ethiopia
- Kinetics of Retinol and TBS Among Lactating Senegalese Women Living in an Urban Setting and the Relationship Between Their TBS and Those of Their Infants (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |